An article from the "Canada Communicable Disease Report" (CCDR), Volume 36 • ACS-9 September 2010. In this statement, the National Advisory Committee on Immunization (NACI) reviews the one available measles-mumps-rubella-varicella (MMRV) vaccine, Priorix-Tetra™, GlaxoSmithKline (GSK) Inc., authorized for use in Canada, and makes recommendations for its use. Measles-mumps-rubella (MMR) vaccine has been available in Canada since the 1970s, and univalent varicella vaccine has been available since 1998. MMR and univalent varicella vaccines cannot be administered in the same syringe, necessitating two injections at separate sites. The availability of a combined MMRV vaccine enables vaccine providers to reduce the number of injections. Source: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/10pdf/36-acs-9.pdf
- Recommendation
- Americas
- Canada
- health policy
- Measles
- Mumps
- Varicella
- Rubella
